Evidence map›Paper›PMID 31888938›Full record

ArticleBMJ open2019

Supporting people with type 2 diabetes in effective use of their medicine through mobile health technology integrated with clinical care (SuMMiT-D Feasibility): a randomised feasibility trial protocol.

Andrew Farmer, Julie Allen, Kiera Bartlett, Peter Bower, Yuan Chi, David French, Bernard Gudgin, Emily A Holmes, Robert Horne, Dyfrig A Hughes and 13 more

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 7 institutions in 2 countries.

Andrew FarmerNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK andrew.farmer@phc.ox.ac.uk.ORCID 0000-0002-6170-4402
Julie AllenNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Kiera BartlettThe Division of Psychology and Mental Health, The University of Manchester, Manchester, UK.
Peter BowerDivision of Population Health, Health Services Research & Primary Care, The University of Manchester, Manchester, UK.
Yuan ChiThe Institute of Biomedical Engineering, University of Oxford, Oxford, UK.
David FrenchThe Division of Psychology and Mental Health, The University of Manchester, Manchester, UK.ORCID 0000-0002-7663-7804
Bernard GudginPatient Representative, Oxford, UK.
Emily A HolmesSchool of Health Sciences, Bangor University, Bangor, UK.
Robert HorneUCL School of Pharmacy, University College London, London, UK.
Dyfrig A HughesCentre for Health Economics and Medicines Evaluation, Bangor University, Bangor, UK.
Cassandra KenningInstitute of Population Health, The University of Manchester, Manchester, UK.ORCID 0000-0001-6041-4051
Louise LocockHealth Service Research, University of Aberdeen, Aberdeen, UK.
Jenny McSharryHealth Behaviour Change Research Group, School of Psychology, National University of Ireland Galway, Galway, Ireland.
Lisa MilesDivision of Psychology and Mental Health, The University of Manchester, Manchester, UK.
Nikki NewhouseORCID 0000-0001-9002-3588
Rustam ReaNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Evgenia RigaNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Lionel TarassenkoThe Institute of Biomedical Engineering, University of Oxford, Oxford, UK.
Carmelo VelardoThe Institute of Biomedical Engineering, University of Oxford, Oxford, UK.
Nicola WilliamsNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Veronika WilliamsNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Ly-Mee YuNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
SuMMiT-D Collaborative Group
University of Oxford · GBUniversity of Manchester · GBBangor University · GBManchester Academic Health Science Centre · GBOllscoil na Gaillimhe – University of Galway · IEUniversity College London · GBUniversity of Aberdeen · GB

Funding

Chief Scientist Office HSRU2Department of Health RP-PG-1214-20003
6 · The paper itself

Abstract

introductionType 2 diabetes is common, affecting over 400 million people worldwide. Risk of serious complications can be reduced through use of effective treatments and active self-management. However, people are often concerned about starting new medicines and face difficulties in taking them regularly. Use of brief messages to provide education and support self-management, delivered through mobile phone-based text messages, can be an effective tool for some long-term conditions. We have developed messages aiming to support patients' self-management of type 2 diabetes in the use of medications and other aspects of self-management, underpinned by theory and evidence. The aim of this trial is to determine the feasibility of a large-scale clinical trial to test the effectiveness and cost-effectiveness of the intervention, compared with usual care. METHODS AND ANALYSIS: The feasibility trial will be a multicentre individually randomised, controlled trial in primary care recruiting adults (≥35 years) with type 2 diabetes in England. Consenting participants will be randomised to receive short text messages three times a week with messages designed to produce change in medication adherence or non-health-related messages for 6 months. The aims are to test recruitment methods, retention to the study, the feasibility of data collection and the mobile phone and web-based processes of a proposed definitive trial and to refine the text messaging intervention. The primary outcome is the rate of recruitment to randomisation of participants to the trial. Data, including patient reported measures, will be collected online at baseline and the end of the 6-month follow-up period. With 200 participants (100 in each group), this trial is powered to estimate 80% follow-up within 95% CIs of 73.8% to 85.3%. The analysis will follow a prespecified plan. ETHICS AND DISSEMINATION: Ethics approval was obtained from the West of Scotland Research Ethics Committee 05. The results will be disseminated through conference presentations, peer-reviewed journals and will be published on the trial website: www.summit-d.org (SuMMiT-D (SUpport through Mobile Messaging and digital health Technology for Diabetes)). TRIAL REGISTRATION NUMBER: ISRCTN13404264.

Indexed as

AdultAgedDiabetes Mellitus, Type 2Feasibility StudiesFemaleHumansHypoglycemic AgentsMaleMiddle AgedPatient Education as TopicRandomized Controlled Trials as TopicSelf-ManagementTelemedicineHypoglycemic Agentsbehavioural change interventiondigital healthfeasibility studyprimary careprocess evaluationrandomised controlled trialType 2 diabetes

Identifiers

PMID31888938
PMCPMC6937131
OpenAlexW2992250826

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.